Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Abstract Background The Phase III PINNACLE studies assessed the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), a dual long-acting bronchodilator for chronic obstructive pulmonary disease (COPD). Here we present a pre-specified pooled analysis of PINNACLE-1,...

Full description

Bibliographic Details
Main Authors: Fernando J. Martinez, Brian J. Lipworth, Klaus F. Rabe, David J. Collier, Gary T. Ferguson, Sanjay Sethi, Gregory J. Feldman, Gerald O’Brien, Martin Jenkins, Colin Reisner
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Respiratory Research
Subjects:
Chronic obstructive pulmonary disease
Clinically important deterioration
Exacerbations
Fixed-dose combination
Formoterol fumarate dihydrate
GFF MDI
Online Access:http://link.springer.com/article/10.1186/s12931-020-01388-y

Internet

http://link.springer.com/article/10.1186/s12931-020-01388-y

Similar Items